Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.5%

2 terminated/withdrawn out of 57 trials

Success Rate

93.1%

+6.6% vs industry average

Late-Stage Pipeline

21%

12 trials in Phase 3/4

Results Transparency

2 of 27 completed trials have results

Key Signals

12 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

20(47.6%)

Phase 3

9(21.4%)

Phase 1

5(11.9%)

N/A

4(9.5%)

Phase 4

3(7.1%)

Early Phase 1

1(2.4%)

42Total

Phase 2(20)

Phase 3(9)

Phase 1(5)

N/A(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials

NCT04307576Phase 3Recruiting

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT06707493Phase 2Recruiting

Ivosidenib as Post-HSCT Maintenance for AML

Role: collaborator

NCT05292664Phase 1Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Role: collaborator

NCT05581030Phase 1Recruiting

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Role: collaborator

NCT05062889Phase 2Suspended

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Role: collaborator

NCT03020030Phase 3Active Not Recruiting

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Role: collaborator

NCT06780930Phase 3Active Not Recruiting

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Role: lead

NCT05184842Phase 2Recruiting

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Role: collaborator

NCT06245356Phase 2Recruiting

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Role: collaborator

NCT06081829Phase 2Active Not Recruiting

A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Role: lead

NCT03117751Phase 2Active Not Recruiting

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Role: collaborator

NCT07259733Not ApplicableRecruiting

Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)

Role: collaborator

NCT03044587Phase 2Completed

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Role: collaborator

NCT04489173Phase 2Active Not Recruiting

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

Role: collaborator

NCT05857735Completed

Kuwait Heart Foundation Registry of Acute Coronary Events

Role: collaborator

NCT05609994Phase 1Recruiting

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Role: collaborator

NCT07071844Phase 2Not Yet Recruiting

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Role: collaborator

NCT07028424Phase 2Not Yet Recruiting

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Role: collaborator

NCT03764553Phase 2Active Not Recruiting

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Role: collaborator

NCT05118178Completed

Atherosclerosis in Chemotherapy-related Cardiotoxicity

Role: collaborator